Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

The Role of HRD Testing in Cancer

ESMO-Webinar-HRD-Testing-1000x250
Start date
10 Nov 2021
End date
10 Nov 2021

This webinar aims to review and discuss different methods for HRD testing, the clinical aspects of HRD as a predictive/prognostic biomarker in ovarian cancer and to understand the role of HRD testing in other tumour types.

Chair

Rowan Miller

Speakers

James Brenton, Violeta Serra, Wassim Abida

Programme

  • Welcome and Introduction - Where are we now with HRD as a Predictive/Prognostic Biomarker in Ovarian Cancer, Dr. Rowan Miller, University College London, St Bartholomew's Hospitals, London, UK
  • Evaluating HRD Status Using Gene Signatures and Scar Assays, Prof. James Brenton, Cancer Research UK Cambridge Institute, Cambridge Research Institute, Cambridge, UK
  • Functional HRD Assays – Ready for Prime Time?, Dr. Violeta Serra, Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
  • HRD Testing Beyond Ovarian Cancer - The Role in GU Cancers and Others, Dr. Wassim Abida, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, US
  • Q&A
  • Closing Remarks, Dr. Rowan Miller, University College London, St Bartholomew's Hospitals, London, UK

Learning Objectives

  • To understand the role of HRD testing in cancer
  • To understand different methods for HRD testing
  • To understand the clinical aspects of HRD as a predictive/prognostic biomarker in ovarian cancer
  • To understand the role of HRD testing beyond ovarian cancer

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings